• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Recent Advances in the Study of 1H,4H,5H,6H-cyclopenta[d]imidazole (CAS: 10442-94-1): A Comprehensive Research Brief

The compound 1H,4H,5H,6H-cyclopenta[d]imidazole (CAS: 10442-94-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent studies have highlighted the versatility of 1H,4H,5H,6H-cyclopenta[d]imidazole as a scaffold for the design of novel bioactive molecules. Its fused bicyclic structure, featuring both imidazole and cyclopentane rings, offers a unique platform for the development of compounds with diverse pharmacological properties. Researchers have explored its potential as a precursor for the synthesis of kinase inhibitors, antimicrobial agents, and anti-inflammatory drugs, among others.

One of the most notable advancements in this area is the development of efficient synthetic routes for 1H,4H,5H,6H-cyclopenta[d]imidazole and its derivatives. A study published in the Journal of Medicinal Chemistry (2023) described a novel catalytic method for the regioselective functionalization of this scaffold, enabling the rapid generation of structurally diverse analogs. This breakthrough has significantly expanded the chemical space available for drug discovery efforts.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated promising results. For instance, certain derivatives of 1H,4H,5H,6H-cyclopenta[d]imidazole have shown potent inhibitory activity against specific protein kinases involved in cancer progression. Another study reported in Bioorganic & Medicinal Chemistry Letters (2024) identified a series of analogs with significant antibacterial activity against multidrug-resistant strains, suggesting potential applications in addressing the global antibiotic resistance crisis.

The mechanism of action of these compounds is currently under investigation. Preliminary data suggest that the imidazole moiety plays a crucial role in target binding, while the cyclopentane ring contributes to the overall pharmacokinetic properties of the molecules. Computational modeling studies have provided valuable insights into the structure-activity relationships of these compounds, facilitating the rational design of more potent and selective derivatives.

From a pharmaceutical development perspective, recent pharmacokinetic studies have evaluated the drug-like properties of 1H,4H,5H,6H-cyclopenta[d]imidazole derivatives. While some challenges remain in terms of metabolic stability and bioavailability, several lead compounds have demonstrated favorable profiles in preclinical testing. Industry reports indicate that at least two pharmaceutical companies have initiated development programs based on this scaffold.

Looking ahead, researchers anticipate that further exploration of 1H,4H,5H,6H-cyclopenta[d]imidazole derivatives will yield additional therapeutic candidates. Current efforts are focused on optimizing the scaffold for specific disease targets, improving synthetic methodologies, and investigating combination therapies. The compound's versatility suggests it may find applications beyond its current scope, potentially in areas such as neurodegenerative diseases or metabolic disorders.

In conclusion, the growing body of research on 1H,4H,5H,6H-cyclopenta[d]imidazole (CAS: 10442-94-1) underscores its importance as a valuable scaffold in medicinal chemistry. The recent advances in synthesis, biological evaluation, and mechanistic understanding position this compound as a promising candidate for future drug development efforts. Continued investigation of its derivatives is expected to yield novel therapeutic agents addressing various unmet medical needs.

• 146953-86-8(1H-Imidazole, 4-butyl-)
• 110453-29-7(1H-Imidazole, 4-pentyl-)
• 3752-24-7(4,5,6,7-tetrahydro-1H-1,3-benzodiazole)
• 16930-80-6(1H-Cyclooctadecimidazole,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19-hexadecahydro-)
• 260050-43-9(1H-Imidazole, 5-heptyl-)
• 6200-66-4(4,5,6,7,8,9-Hexahydro-1H-cycloocta[d]imidazole)
• 10493-90-0(1,4,5,6,7,8-hexahydro-Cycloheptimidazole)
• 24363-69-7(1H-Imidazole, 4,5-dipropyl-)
• 3291-07-4(2-methyl-4,5,6,7-tetrahydro-1H-1,3-benzodiazole)
• 122246-22-4(1H-Imidazole, 4-hexyl-)